Neonatal Conjunctivitis Therapeutics Market to Register a Growth Rate of CAGR XX% During the Forecast Period 2018 - 2026

07/apr/2020 12:48:29 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Conjunctivitis is also known as pink eye, since the inflammation of the conjunctiva of the eye due to infection makes the white part of the eye to look red or pink in color. Neonatal Conjunctivitis is also known as Opthalmia Neonatorum. Neonatal conjunctivitis manifests in the infant within the first 28 days of being born.

It is generally acquired during the passage of the neonate through the infected birth canal. Neonatal conjunctivitis by non-sexually transmitted bacteria is less common when compared to the infection caused by sexually transmitted organisms.

Some of the common microorganisms that cause the infection include Chlamydia trachomatis, Staphylococcus aureus, Staphylococcus epidermis, Esterichia coli, Neisseria gonorrhea, other gram-negative bacteria and Herpes Simplex Virus. Neonatal Conjunctivitis can be caused not only by bacteria but also by chemical agents and viral agents.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/23158

Definitive laboratory testing is required for proper diagnosis and identification of the causative organism. However, prophylactic treatment could be used to reduce the incidence of neonatal conjunctivitis this includes the use of silver nitrate that could prevent any infections in the neonate.

Factor Driving Neonatal Conjunctivitis Therapeutics

Increasing birth rate across the world drives the growth of the neonatal conjunctivitis therapeutics market. Furthermore, the increase in the prevalence of infectious diseases in particular neonatal conjunctivitis also drives the growth of the market.

Increased awareness and screening of pregnant females for sexually transmitted diseases increases the treatment and precaution rate for neonatal conjunctivitis there by driving the growth of the neonatal conjunctivitis therapeutics market.

Increasing R&D investments in new drug development is also fueling the growth of the neonatal conjunctivitis therapeutics market.

Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/23158

Neonatal Conjunctivitis Therapeutics

Chemically induced neonatal conjunctivitis generally recovers on its own and thus does not require any treatment. Given the high incidence of neonatal conjunctivitis, especially with Chlamydia conjunctivitis, systemic therapy is generally opted in such cases.

A 14 day course of erythromycin is prescribed to most patients. Although macrolide antibiotics such as azithromycin, clarithromycin and roxithromycin may be more affective in cases of infection with Chlamydia, they are not well studied in neonatal conjunctivitis.

Gonococcal conjunctivitis in neonates can be treated with ceftriaxone that is administered either intramuscularly or intravenously. Herpetic conjunctivitis in neonates can be treated using topical trifluridine solution.

Regional Market Outlook

Globally, the neonatal conjunctivitis therapeutic market can be divided into North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America dominates the market for neonatal conjunctivitis therapeutics.

High prevalence of sexually transmitted diseases and increasing awareness about neonatal conjunctivitis are some of the driving factors for the growth of the market in North America.

The market in Asia-Pacific is expected to grow at a rapid rate since the region is a highly lucrative market for neonatal conjunctivitis therapeutics. This is also due to the prevalence of infection and poor hygiene conditions in the developing countries.

Competition Outlook

Examples of some of the key participants in the non-union fractures market are Merck & Co. Inc., Akorn Inc, Pfizer, Bayer AG, and others.

For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/23158

More About the Report –

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Molecular Diagnostics Market –

Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.

Next-Generation Sequencing Market – 

Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.

Ophthalmology devises Market –

Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.

Intravenous Iron Drugs Market – 

Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.

Syndromes Progressive Ataxia Weakness Disorders Market – 

Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl